Published: Mar 10, 2021
Recognized revenue of $29.4 million
Six assets in the Company’s milestone and royalty portfolio advanced to Phase 2 clinical development
Completed $24.6 million Series A Perpetual Preferred Stock offering paying a 8.625% dividend
Ended 2020 with $84.2 million in cash
EMERYVILLE, Calif., March 10, 2021 (GLOBE NEWSWIRE) XOMA Corporation (Nasdaq: XOMA) announced its fourth quarter and full-year 2020 financial results and business highlights.
“Our success in 2020 is a direct reflection of our strategy at work. As a result of the commitment by our partners to improve human health, we saw multiple programs advance further in the clinic. Novartis, Merck, Takeda, Incyte, Rezolute, and an undisclosed partner individually launched Phase 2 clinical studies with an asset in the XOMA portfolio. XOMA’s shareholders benefited from the milestones we received as our partners made these advancements, highlighted by the $25 million milestone we ear